{
  "docId": "019de071-4e1f-74a8-b040-3577ed32c01f",
  "docSlug": "716a1960d23114ac9a8076dbc94bca80",
  "documentTitle": "Tenaya Therapeutics | IPO Presentation Deck | 36 slides",
  "authorId": "tenaya-therapeutics",
  "authorName": "Tenaya Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 14,
  "pageCount": 36,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes bar chart, line chart, and Kaplan-Meier survival curve.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-4e1f-74a8-b040-3577ed32c01f/14",
  "deckHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f",
  "deckJsonHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f.json",
  "deckAnchorHref": "/decks/019de071-4e1f-74a8-b040-3577ed32c01f#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Ejection Fraction (%) comparison between WT, Control, and AAV:mMYBPC3",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6132b84d-e568-43d0-9e35-3fe978da22df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.7,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b707a9b-fd9c-4f8b-a72a-27f31775ecb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Ejection Fraction (%) over time (Weeks Post Delivery)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc89913c-9954-46ed-8057-f41e3898a140",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Significant and Durable Improvement in Heart Function (13 Months Post-Treatment)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "255de620-cf95-490b-97c3-f7ea17911660",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.7,
        "y": 0.18
      },
      "kind": "list",
      "text": "Survival Benefit (16 Months Post-Treatment)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47d07ba1-5aa4-4468-99db-6c390d341d31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "Significant Disease Reversal and Survival Benefit Using AAV:MYBPC3 in Severe Model. Effect Maintained 16 Months Post-Treatment After Single Dose.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64b68c1b-3e73-465f-88cb-e55cc7495411",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MYBPC3 Gene Therapy Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aae4f924-47ea-4a65-912c-722a0ecbf96f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 13,
      "beatId": "bfe54e44-7b0c-4c52-9e6e-5fc899bfd36c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The 'MYBPC3 Gene Therapy Program', 'PKP2 Gene Therapy Program', and 'HDAC6i Small Molecule Program' slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 14,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "df6b89c1-2ac4-4915-b2b4-e07a3dc8a05f",
      "evidence": "The 'Significant Disease Reversal and Survival Benefit Using AAV:MYBPC3 in Severe Model' slide",
      "position": 1,
      "objective": "Testing the hypothesis of AAV:MYBPC3 efficacy",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}